NRx Pharmaceuticals, Inc. (NASDAQ:NRXPGet Rating) major shareholder Daniel C. Javitt sold 243,596 shares of the business’s stock in a transaction dated Friday, June 3rd. The stock was sold at an average price of $0.70, for a total value of $170,517.20. Following the sale, the insider now owns 12,859,080 shares in the company, valued at approximately $9,001,356. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Major shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.

Shares of NRXP stock remained flat at $$0.65 during trading hours on Tuesday. The stock had a trading volume of 875,616 shares, compared to its average volume of 1,105,109. NRx Pharmaceuticals, Inc. has a 1-year low of $0.49 and a 1-year high of $26.24. The stock has a market cap of $43.32 million, a PE ratio of -0.09 and a beta of 0.72. The company has a debt-to-equity ratio of 0.02, a quick ratio of 3.83 and a current ratio of 3.83. The firm has a 50-day moving average price of $1.61 and a two-hundred day moving average price of $3.16.

NRx Pharmaceuticals (NASDAQ:NRXPGet Rating) last issued its earnings results on Monday, May 16th. The company reported ($0.25) EPS for the quarter.

Hedge funds and other institutional investors have recently modified their holdings of the stock. Penserra Capital Management LLC purchased a new stake in NRx Pharmaceuticals in the third quarter valued at approximately $27,000. JPMorgan Chase & Co. boosted its position in NRx Pharmaceuticals by 2,345.3% in the fourth quarter. JPMorgan Chase & Co. now owns 5,184 shares of the company’s stock valued at $25,000 after buying an additional 4,972 shares during the last quarter. Royal Bank of Canada purchased a new stake in NRx Pharmaceuticals in the second quarter valued at approximately $93,000. Bank of New York Mellon Corp purchased a new stake in NRx Pharmaceuticals in the first quarter valued at approximately $25,000. Finally, State Street Corp purchased a new stake in NRx Pharmaceuticals in the fourth quarter valued at approximately $49,000. Hedge funds and other institutional investors own 3.87% of the company’s stock.

NRx Pharmaceuticals Company Profile (Get Rating)

NRX Pharmaceuticals, Inc, a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior.

Featured Stories

Receive News & Ratings for NRx Pharmaceuticals Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for NRx Pharmaceuticals and related companies with’s FREE daily email newsletter.

Source link